Showing 2491-2500 of 2894 results for "".
- Aesthetics Biomedical Inc. Scores Third U.S. Patent for SoME Skincarehttps://modernaesthetics.com/news/aesthetics-biomedical-inc-scores-third-us-patent-for-some-skincare/2473277/Aesthetics Biomedical Inc. scored its third U.S. patent for “biological preserving composition and methods of use” for its SoME skincare product line. The patent covers topical compositions for combining biologics with skincare preserving the exclusivity of SoME Skincar
- The New MedSpa App Set To Improve Ease of Appointment Bookinghttps://modernaesthetics.com/news/the-new-medspa-app-set-to-improve-ease-of-appointment-booking/2473276/According to UpKeep Founder and CEO Tiffany Faither Demers, it is well known that within the medspa industry that appointment booking often proves difficult for customer. She created created
- Study Assesses What Makes Lips Most Attractivehttps://modernaesthetics.com/news/study-assesses-what-makes-lips-most-attractive/2473273/Although social media and celebrity icons are driving increased demand for fuller, "pouty" lips, a new study in the August issue of Plastic and Reconstructive Surgery found a natural-looking and harmonious app
- Aesthetics Biomedical Adds Two Executives to its Leadership Teamhttps://modernaesthetics.com/news/aesthetics-biomedical-adds-two-executives-to-its-leadership-team/2473271/Aesthetics Biomedical Inc. (ABM), in its ongoing efforts to meet the increasing demand for its aesthetic products and distribution growth, is continuing to build its executive team. The company recently hired industry experts Derek Harmon as Vice Pres
- FDA Nod for Sientra’s Low Plus Profile Projection Breast Implanthttps://modernaesthetics.com/news/fda-nod-for-sientras-low-plus-profile-projection-breast-implant-1/2473263/The U.S. Food and Drug Administration (FDA) approved Sientra’s Low Plus Profile Projection Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction. This product will be commercially available for board-certi
- Galderma to Participate in New York's PrideFest Sundayhttps://modernaesthetics.com/news/galderma-to-participate-in-new-yorks-pridefest-sunday/2473261/Galderma is participating in New York City's official LGBTQIA+ Pride (NYC Pride) event. This month marks the official launch of Restylane's "XpresYourself" communications campaign, which gives a nod to Restylane's XpresHAn Technology™, a u
- Ice-slurry Injections May Melt Subcutaneous Fathttps://modernaesthetics.com/news/ice-slurry-injections-may-melt-subcutaneous-fat/2473260/Cryolipolysis with injectable ice-slurry may soon become an efficient, effective and customizable method of body sculpting, according to new research ine Lasers in Surgery and Medicine.
- Bausch Health Suspends Plans for Solta IPOhttps://modernaesthetics.com/news/bausch-health-suspends-plans-for-solta-ipo-1/2473255/Bausch Health Companies Inc. is suspending its plans for the Solta IPO due to challenging market conditions and other factors. Bausch Health stated that the interests of the Company's stakeholders are best served in the near-term by focusing on driving Solta's revenue, profits a
- New from Senté: Even Tone Mineral Sunscreenhttps://modernaesthetics.com/news/new-from-sente-even-tone-mineral-sunscreen/2473252/Senté has launched new tinted sunscreen formulas that protect the skin from damage caused by visible light in addition to UV rays. Even Tone Mineral Sunscreen is specifically designed to promote even skin tone in every complexion, the company says.
- Top-line Phase 3 Data Promising for Galderma's RelabotulinumtoxinAhttps://modernaesthetics.com/news/top-line-phase-3-data-promising-for-galdermas-relabotulinumtoxina/2473250/Galderma’s investigational RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, improves both glabellar and lateral canthal lines with a rapid onset of action and a long duration up to six months, according to top-line phase 3 data presen